Podocalyxin promotes glioblastoma multiforme cell invasion and proliferation by inhibiting angiotensin-(1-7)/Mas signaling

Oncology Reports

Volumn 33, Issue 5, 2015, Pages 2583-2591

  Liu, Bo ^a   Liu, Yu ^a   Jiang, Yugang ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Angiotensin (1 7); Glioblastoma multiforme; Invasion; Mas; Matrix metalloproteinase 9; Phosphatidylinositol 3 kinase; Podocalyxin; Proliferation

Indexed keywords

ANGIOTENSIN[1-7]; BUPARLISIB; GELATINASE B; MAS PROTEIN; MESSENGER RNA; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PODOCALYXIN; UNCLASSIFIED DRUG; ANGIOTENSIN I; ANGIOTENSIN I (1-7); G PROTEIN COUPLED RECEPTOR; PEPTIDE FRAGMENT; PROTO-ONCOGENE PROTEINS C-MAS-1; SIALOGLYCOPROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CELL INVASION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HORMONE INHIBITION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; UPREGULATION; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR INVASION;

ANGIOTENSIN I; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; PEPTIDE FRAGMENTS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; RECEPTORS, G-PROTEIN-COUPLED; SIALOGLYCOPROTEINS; SIGNAL TRANSDUCTION;

EID: 84927145708     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.3813     Document Type: Article

References (35)

1. Zhang Z and Lin CC: Taking advantage of neural development to treat glioblastoma. Eur J Neurosci 40:2859-2866, 2014.
2. Wen PY and Kesari S: Malignant gliomas in adults. N Engl J Med 359:492-507, 2008.
3. Giese A, Bjerkvig R, Berens ME and Westphal M: Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 21:1624-1636, 2003.
4. Nielsen JS and McNagny KM: The role of podocalyxin in health and disease. J Am Soc Nephrol 20:1669-1676, 2009.
5. Riccioni R, Calzolari A, Biffoni M, et al: Podocalyxin is expressed in normal and leukemic monocytes. Blood Cells Mol Dis 37:218-225, 2006.
6. Kelley TW, Huntsman D, McNagny KM, Roskelley CD and Hsi ED: Podocalyxin: a marker of blasts in acute leukemia. Am J Clin Pathol 124:134-142, 2005.
7. Yasuoka H, Tsujimoto M, Hirokawa M, et al: Podocalyxin expression in undifferentiated thyroid carcinomas. J Clin Pathol 61:1228-1229, 2008.
8. Hsu YH, Lin WL, Hou YT, et al: Podocalyxin EBP50 ezrin molecular complex enhances the metastatic potential of renal cell carcinoma through recruiting Rac1 guanine nucleotide exchange factor ARHGEF7. Am J Pathol 176:3050-3061, 2010.
9. Sizemore S, Cicek M, Sizemore N, Ng KP and Casey G: Podocalyxin increases the aggressive phenotype of breast and prostate cancer cells in vitro through its interaction with ezrin. Cancer Res 67:6183-6191, 2007.
10. Somasiri A, Nielsen JS, Makretsov N, et al: Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression. Cancer Res 64:5068-5073, 2004.
11. Wu H, Yang L, Liao D, Chen Y, Wang W and Fang J: Podocalyxin regulates astrocytoma cell invasion and survival against temozolomide. Exp Ther Med 5:1025-1029, 2013.
12. Kaprio T, Fermér C, Hagström J, Mustonen H, Böckelman C, Nilsson O and Haglund C: Podocalyxin is a marker of poor prognosis in colorectal cancer. BMC Cancer 14:493, 2014.
13. De Gasparo M, Catt KJ, Inagami T, Wright JW and Unger T: International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 52:415-472, 2000.
14. Ni L, Feng Y, Wan H, Ma Q, Fan L, Qian Y, Li Q, Xiang Y and Gao B: Angiotensin-(1-7) inhibits the migration and invasion of A549 human lung adenocarcinoma cells through inactivation of the PI3K/Akt and MAPK signaling pathways. Oncol Rep 27:783-790, 2012.
15. George AJ, Thomas WG and Hannan RD: The renin angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer 10:745-759, 2010.
16. Röcken C, Röhl FW, Diebler E, Lendeckel U, Pross M, Carl-McGrath S and Ebert MP: The angiotensin II/angiotensin II receptor system correlates with nodal spread in intestinal type gastric cancer. Cancer Epidemiol Biomarkers Prev 16:1206-1212, 2007.
17. Ferreira AJ, Murça TM, Fraga-Silva RA, Castro CH, Raizada MK and Santos RA: New cardiovascular and pulmonary therapeutic strategies based on the angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor axis. Int J Hypertens 2012:147825, 2012.
18. Raizada MK and Ferreira AJ: ACE2: a new target for cardiovascular disease therapeutics. J Cardiovasc Pharmacol 50:112-119, 2007.
19. Der Sarkissian S, Huentelman MJ, Stewart J, Katovich MJ and Raizada MK: ACE2: a novel therapeutic target for cardiovascular diseases. Prog Biophys Mol Biol 91:163-198, 2006.
20. Rice GI, Thomas DA, Grant PJ, Turner AJ and Hooper NM: Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J 383:45-51, 2004.
21. Ferreira AJ and Santos RA: Cardiovascular actions of angiotensin-(1-7). Braz J Med Biol Res 38:499-507, 2005.
22. Gomes ER, Santos RA and Guatimosim S: Angiotensin-(1-7) - mediated signaling in cardiomyocytes. Int J Hypertens 2012:493129, 2012.
23. Garcia-Espinosa MA, Lesser GJ, Debinski W, Tallant EA and Gallagher PE: Angiotensin-(1-7), a peptide hormone with therapeutic potential for the treatment of glioblastomas (abstract). In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar. 31-Apr. 4; Chicago, Illinois. Philadelphia (PA): AACR. Cancer Res 72(Suppl 8): Abs. 1938, 2012. doi:1538-7445. AM2012-1938.
24. Gironacci MM, Adamo HP, Corradi G, Santos RA, Ortiz P and Carretero OA: Angiotensin (1-7) induces MAS receptor internalization. Hypertension 58:176-181, 2011.
25. Wang B, Feng P, Xiao Z and Ren EC: LIM and SH3 protein 1 (Lasp1) is a novel p53 transcriptional target involved in hepatocellular carcinoma. J Hepatol 50:528-537, 2009.
26. Feng Y, Hu J, Ma J, Feng K, Zhang X, Yang S, Wang W, Zhang J and Zhang Y: RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways. Eur J Cancer 47:2353-2363, 2011.
27. Jo YK, Park SJ, Shin JH, Kim Y, Hwang JJ, Cho DH and Kim JC: ARP101, a selective MMP-2 inhibitor, induces autophagyassociated cell death in cancer cells. Biochem Biophys Res Commun 404:1039-1043, 2011.
28. Qazi H, Shi ZD and Tarbell JM: Fluid shear stress regulates the invasive potential of glioma cells via modulation of migratory activity and matrix metalloproteinase expression. PLoS One 6:e20348, 2011.
29. Fekete A, Bogel G, Pesti S, Péterfi Z, Geiszt M and Buday L: EGF regulates tyrosine phosphorylation and membrane-translocation of the scaffold protein Tks5. J Mol Signal 8:8, 2013.
30. Yang N, Hui L, Wang Y, Yang H and Jiang X: SOX2 promotes the migration and invasion of laryngeal cancer cells by induction of MMP-2 via the PI3K/Akt/mTOR pathway. Oncol Rep 31:2651-2659, 2014.
31. Yoon SO, Shin S, Lee HJ, Chun HK and Chung AS: Isoginkgetin inhibits tumor cell invasion by regulating phosphatidylinositol 3-kinase/Akt-dependent matrix metalloproteinase-9 expression. Mol Cancer Ther 5:2666-2675, 2006.
32. Li Y, Liao Q, Li K, Zhong D, Weng X and Mi M: Knockdown of endothelin A receptor expression inhibits osteosarcoma pulmonary metastasis in an orthotopic xenograft mouse model. Mol Med Rep 5:1391-1395, 2012.
33. Wegman-Ostrosky T, Soto-Reyes E, Vidal-Millán S and Sánchez-Corona J: The renin-angiotensin system meets the hallmarks of cancer. J Renin Angiotensin Aldosterone Syst: Aug. 9, 2013 (Epub ahead of print).
34. Silva DM, Vianna HR, Cortes SF, Campagnole-Santos MJ, Santos RAS and Lemos VS: Evidence for a new angiotensin-(1-7) receptor subtype in the aorta of Sprague-Dawley rats. Peptides 28:702-707, 2007.
35. Medeiros MA, França MS, Boileau G, Juliano L and Carvalho KM: Specific fluorogenic substrates for neprilysin (neutral endopeptidase, EC 3.4.24.11) which are highly resistant to serine- and metalloproteases. Braz J Med Biol Res 30:1157-1162, 1997.